Skye Bioscience, Inc. (SKYE)

OTCMKTS: SKYE · Delayed Price · USD
0.00 (0.00%)
Nov 28, 2023, 2:56 PM EST - Market closed

Company Description

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases.

The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension.

It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy.

It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021.

The company is headquartered in San Diego, California.

Skye Bioscience, Inc.
Country United States
Founded 2012
Industry Biotechnology
Sector Healthcare
Employees 11
CEO Punit S. Dhillon B.A., BA

Contact Details

11250 El Camino Real, Suite 100
San Diego, California 92130
United States
Phone (858) 410-0266

Stock Details

Ticker Symbol SKYE
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001516551
CUSIP Number 83086J101
ISIN Number US83086J1016
Employer ID 45-0692882
SIC Code 2834

Key Executives

Name Position
Punit S. Dhillon B.A., BA Executive Chairman, President, Chief Executive Officer and Secretary
Kaitlyn Melanie Arsenault CPA Chief Financial Officer
Dr. Christopher G. Twitty Ph.D. Chief Scientific Officer
Tu Diep M.Sc. Chief Development Officer

Latest SEC Filings

Date Type Title
Nov 14, 2023 10-Q Quarterly Report
Nov 7, 2023 8-K Current Report
Oct 17, 2023 DEF 14C Filing
Oct 3, 2023 8-K Current Report
Oct 3, 2023 PRE 14C Filing
Sep 7, 2023 8-K Current Report
Sep 1, 2023 8-K/A [Amend] Current report
Aug 29, 2023 D Notice of Exempt Offering of Securities
Aug 28, 2023 SC 13G Statement of acquisition of beneficial ownership by individuals
Aug 28, 2023 SC 13D General statement of acquisition of beneficial ownership